Evidence map›Paper›PMID 40654902›Full record

ArticlebioRxiv : the preprint server for biology2025

Differential cell signaling testing for cell-cell communication inference from single-cell data by dominoSignal.

Jacob T Mitchell, Orian Stapleton, Kavita Krishnan, Sushma Nagaraj, Dmitrijs Lvovs, Christopher Cherry, Amanda Poissonnier, Wes Horton, Andrew Adey, Varun Rao and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jacob T MitchellDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-5370-9692
Orian StapletonDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Kavita KrishnanDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Sushma NagarajDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Dmitrijs LvovsInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Christopher CherryDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Amanda PoissonnierDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
Wes HortonDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
Andrew AdeyDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
Varun RaoInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Amanda HuffDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Jacquelyn W ZimmermanDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Luciane T KagoharaDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Neeha ZaidiDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Lisa M CoussensDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
Elizabeth M JaffeeDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Jeniffer H ElisseeffDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Elana J FertigDepartment of Oncology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Transforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 2021 to 2025
$12.7M
Predoctoral Training Program in Human GeneticsT32GM007814 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 1985 to 2021
$10.6M
JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP)U54AG079779 · NIA · JOHNS HOPKINS UNIVERSITY · PI JENNIFER H ELISSEEFF · 2022 to 2026
$6.4M
Biomaterials-directed regenerative immunotherapiesDP1AR076959 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ELISSEEFF, JENNIFER H · 2019 to 2023
$5.7M
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M
Single-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2M
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic CancerK08CA248624 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZAIDI, NEEHA · 2021 to 2025
$1.1M
Investigation of Immunotherapy-induced Alterations to Cellular Communication Networks in Pancreatic Ductal AdenocarcinomaF31CA284525 · NCI · JOHNS HOPKINS UNIVERSITY · PI MITCHELL, JACOB THOMAS · 2024 to 2024
$42k
NCI NIH HHS F31 CA284525NCI NIH HHS K08 CA248624NCI NIH HHS P01 CA247886NCI NIH HHS P30 CA069533NCI NIH HHS U01 CA224012NCI NIH HHS U01 CA253403NIAMS NIH HHS DP1 AR076959NIA NIH HHS U54 AG079779NIGMS NIH HHS T32 GM007814
6 · The paper itself

Abstract

Algorithms for ligand-receptor network inference have emerged as commonly used tools to estimate cell-cell communication from reference single-cell data. Many studies employ these algorithms to compare signaling between conditions and lack methods to statistically identify signals that are significantly different. We previously developed the cell communication inference algorithm Domino, which considers ligand and receptor gene expression in association with downstream transcription factor activity scoring. We developed the dominoSignal software to innovate upon Domino and extend its functionality to test statistically differential cellular signaling. This new functionality includes compilation of active signals as linkages from multiple subjects in a single-cell data set and testing condition-dependent signaling linkage. The software is applicable for analysis of single-cell data sets with multiple subjects as biological replicates as well as with bootstrapped replicates from data sets with few or pooled subjects. We use simulation studies to benchmark the number of subjects in compared groups and cells within an annotated cell type sufficient to accurately identify differential linkages. We demonstrate the application of the Differential Cell Signaling Test (DCST) in the dominoSignal software to investigate consequences of cancer cell phenotypes and immunotherapy on cell-cell communication in tumor microenvironments. These applications in cancer studies demonstrate the ability of differential cell signaling analysis to infer changes to cell communication networks from therapeutic or experimental perturbations, which is broadly applicable across biological systems.

Identifiers

PMID40654902
PMCPMC12248116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.